IKBKE Regulates Renal Cell Carcinoma Progression and Sunitinib Resistance Through the RRM2-AKT Pathway

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2024 Dec 12

PMID 39664571

Authors

Shiwei Liu

Junhong Li

Junyu Zhang

Fangning Wan

Zongyuan Hong

Zhe Hong

Bo Dai

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors (TKIs), such as sunitinib, have emerged as promising agents in renal cell carcinoma (RCC) treatment, particularly in patients at advanced/metastatic clinical stages. However, acquired resistance to sunitinib is common following prolonged clinical treatment in RCC. Increasing evidence has demonstrated a strong correlation between inhibitor of nuclear factor kappa B kinase subunit epsilon (IKBKE) and cancer progression as well as drug resistance. Here, we found that IKBKE is upregulated in RCC tissues and sunitinib-resistant RCC cells. High IKBKE expression is positively correlated with advanced clinical staging and a poor prognosis in RCC. Silencing IKBKE downregulates ribonucleotide reductase M2 (RRM2) and induces cell cycle arrest at G2/M phase, suppressing RCC progression and enhancing sunitinib sensitivity to RCC cells. Mechanistically, IKBKE interacts with and phosphorylates RRM2 to activate the AKT signaling pathway to promotes RCC progression and sunitinib resistance. Notably, the IKBKE inhibitor CYT387 restores sunitinib sensitivity in RCC cells by downregulating RRM2 expression. Collectively, these results indicate that inhibition of IKBKE restrains RCC progression and enhances sunitinib sensitivity by downregulating RRM2 through the RRM2-AKT pathway, suggesting that IKBKE may be a potential therapeutic target for RCC.

References

Shi R, Bao X, Unger K, Sun J, Lu S, Manapov F . Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients. Theranostics. 2021; 11(10):5061-5076. PMC: 7978303. DOI: 10.7150/thno.56202. View

Das A, Shapiro D, Craig J, Abel E . Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC. Nat Rev Urol. 2023; 20(11):654-668. DOI: 10.1038/s41585-023-00776-5. View

Messeha S, Zarmouh N, Antonie L, Soliman K . Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2022; 23(15). PMC: 9368383. DOI: 10.3390/ijms23158329. View

Fischer F, Mies L, Nizami S, Pantazi E, Danielli S, Demarco B . TBK1 and IKKε act like an OFF switch to limit NLRP3 inflammasome pathway activation. Proc Natl Acad Sci U S A. 2021; 118(38). PMC: 8463895. DOI: 10.1073/pnas.2009309118. View

Guo J, Shu S, He L, Lee Y, Kruk P, Grenman S . Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009; 175(1):324-33. PMC: 2708818. DOI: 10.2353/ajpath.2009.080767. View

Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L . Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed Pharmacother. 2020; 133:110996. DOI: 10.1016/j.biopha.2020.110996. View

Hong Z, Xu C, Zheng S, Wang X, Tao Y, Tan Y . Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression. Cell Death Discov. 2023; 9(1):392. PMC: 10597990. DOI: 10.1038/s41420-023-01682-w. View

Fitzgerald K, Motzer R, Lee C . Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nat Rev Urol. 2022; 20(3):179-193. PMC: 10921989. DOI: 10.1038/s41585-022-00666-2. View

Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X . RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh). 2021; 8(18):e2100881. PMC: 8456228. DOI: 10.1002/advs.202100881. View

10.

Rini B, Atkins M . Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009; 10(10):992-1000. DOI: 10.1016/S1470-2045(09)70240-2. View

11.

Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C . IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene. 2012; 32(2):151-9. PMC: 4109158. DOI: 10.1038/onc.2012.39. View

12.

Chung M, Aimaier R, Yu Q, Li H, Li Y, Wei C . RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST. Cell Oncol (Dordr). 2023; 46(5):1399-1413. DOI: 10.1007/s13402-023-00819-4. View

13.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

14.

Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E . First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023; 5():CD013798. PMC: 10158799. DOI: 10.1002/14651858.CD013798.pub2. View

15.

Moller M, Wasel J, Schmetzer J, Weiss U, Meissner M, Schiffmann S . The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways. Int J Mol Sci. 2020; 21(13). PMC: 7369692. DOI: 10.3390/ijms21134721. View

16.

Hong Z, Xiang Z, Zhang P, Wu Q, Xu C, Wang X . Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. Clin Transl Med. 2021; 11(7):e495. PMC: 8299045. DOI: 10.1002/ctm2.495. View

17.

Bainbridge A, Walker S, Smith J, Patterson K, Dutt A, Min Ng Y . IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway. Nucleic Acids Res. 2020; 48(10):5366-5382. PMC: 7261174. DOI: 10.1093/nar/gkaa271. View

18.

Jin J, Xie Y, Zhang J, Wang J, Dai S, He W . Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023; 67:100929. DOI: 10.1016/j.drup.2023.100929. View

19.

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

20.

Rauschner M, Lange L, Husing T, Reime S, Nolze A, Maschek M . Impact of the acidic environment on gene expression and functional parameters of tumors in vitro and in vivo. J Exp Clin Cancer Res. 2021; 40(1):10. PMC: 7786478. DOI: 10.1186/s13046-020-01815-4. View